Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print]

Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir [Epub ahead of print]. Antiviral Therapy. 2017;.

Publication Type:

Journal Article

Authors:

Wyles, David; Mangia, Alessandra; Cheng, Wendy; Shafran, Stephen; Schwabe, Christian; Ouyang, Wen; Hedskog, Charlotte; McNally, John; Brainard, Diana M.; Doehle, Brian P.; Svarovskaia, Evguenia; Miller, Michael D.; Mo, Hongmei; Dvory-Sobol, Hadas

Source:

Antiviral Therapy (2017)

Cited On:

HCV Resistance Primer

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/28650844

Export Citation:

RIS Format

Top